CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Patients with type 2 diabetes mellitus (T2DM) who receive weekly dulaglutide are more likely to achieve fasting blood glucose (FBG) ≤6.7mmol/L at 2 weeks than those treated with metformin, sitagliptin or exenatide twice daily (BID): early…
DOI 10.1055/s-0036-1580783
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Edwards, O Adetunji, H Jung, C Nicolay
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: To investigate the effects of dulaglutide and non-insulin active comparators on FBG values in patients with T2DM in AWARD-1, -3 and -5. Methods: Exploratory post-hoc, by study analyses were performed to determine the percentage of patients receiving dulaglutide 1.5 mg (n = 852), metformin (n = 268), sitagliptin (n = 315) or exenatide BID (n = 276) with FBG ≤6.7mmol/L at baseline and at 2 and 52 weeks. The…
Zitieren
Zitierempfehlung
M Edwards, O Adetunji, H Jung, C Nicolay (2016) Patients with type 2 diabetes mellitus (T2DM) who receive weekly dulaglutide are more likely to achieve fasting blood glucose (FBG) ≤6.7mmol/L at 2 weeks than those treated with metformin, sitagliptin or exenatide twice daily (BID): early and long-term (week 52) data from three clinical studies. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0036-1580783
Mit CareLit weiterarbeiten